专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080081047A1 Anti-Sars Monoclonal Antibodies 有权
标题翻译：抗Sars单克隆抗体
公开(公告)号：US20080081047A1
公开(公告)日：2008-04-03
申请号：US10581613
申请日：2004-12-06
申请人： Jody Berry , Steven Jones , Xin Yong Yuan , Mike Gubbins , Anton Andonov , Hana Weingartl , Mike Drebot , Frank Plummer
发明人： Jody Berry , Steven Jones , Xin Yong Yuan , Mike Gubbins , Anton Andonov , Hana Weingartl , Mike Drebot , Frank Plummer
IPC分类号： A61K39/215 , A61P31/00 , C07K16/10 , C12N15/11 , C12N15/13 , C12P21/08
CPC分类号： C07K16/10 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/76 , G01N33/56983
摘要： Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterisation of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.
摘要翻译：迫切需要识别SARS冠状病毒（SARS-HCoV）的单克隆抗体试剂。在本报告中，我们根据其特异性，结合要求和生物活性，描述mAb对SARS-HCoV的发展和免疫化学表征。通过ELISA进行初步筛选，使用高度纯化的病毒作为包被抗原，导致17个mAb的选择。 5个mAb显示出与变性穗蛋白的Western免疫印迹反应性，其中两个显示出在体外中和SARS-HCoV的能力。另外四种Western免疫印迹阴性mAb也中和了病毒。这些抗体可用于诊断测试，致病性和疫苗研究的开发。

2. 发明授权

US07622112B2 Anti-SARS monoclonal antibodies 有权
标题翻译：抗SARS单克隆抗体
公开(公告)号：US07622112B2
公开(公告)日：2009-11-24
申请号：US10581613
申请日：2004-12-06
申请人： Jody Berry , Steven Jones , Xin Yong Yuan , Mike Gubbins , Anton Andonov , Hana Weingartl , Mike Drebot , Frank Plummer
发明人： Jody Berry , Steven Jones , Xin Yong Yuan , Mike Gubbins , Anton Andonov , Hana Weingartl , Mike Drebot , Frank Plummer
IPC分类号： A61K39/42 , C12N15/09 , C12N15/13 , C12P21/08 , C12P21/00 , C07K16/10 , C07K16/46
CPC分类号： C07K16/10 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/76 , G01N33/56983
摘要： Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterization of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.
摘要翻译：迫切需要识别SARS冠状病毒（SARS-HCoV）的单克隆抗体试剂。在本报告中，我们根据其特异性，结合要求和生物活性，描述mAb对SARS-HCoV的发展和免疫化学表征。通过ELISA进行初步筛选，使用高度纯化的病毒作为包被抗原，导致17个mAb的选择。 5个mAb显示出与变性穗蛋白的Western免疫印迹反应性，其中两个显示出在体外中和SARS-HCoV的能力。另外四种Western免疫印迹阴性mAb也中和了病毒。这些抗体可用于诊断测试，致病性和疫苗研究的开发。

3. 发明申请

US20110112195A1 Potent and Selective Inhibition by Aurinticarboxylic Acid 审中-公开
标题翻译： Aurinticar酸的有效和选择性抑制作用
公开(公告)号：US20110112195A1
公开(公告)日：2011-05-12
申请号：US11570650
申请日：2005-06-15
申请人： Runtao He , Anton Andonov , Jingxin Cao , Mike Drebot , Xueguang Li
发明人： Runtao He , Anton Andonov , Jingxin Cao , Mike Drebot , Xueguang Li
IPC分类号： A61K31/194 , C40B30/02
CPC分类号： A61K31/194 , C12Q1/18 , G01N2500/00 , Y02A50/385 , Y02A50/389 , Y02A50/393
摘要： The severe acute respiratory syndrome virus (SARS) is a coronavirus that instigated regional epidemics in Canada and several Asian countries in 2003. The newly identified SARS coronavirus (SARS-CoV) can be transmitted among humans and cause severe or even fatal illnesses. As preventive vaccine development takes years to complete and adverse reactions have been reported to some veterinary coronaviral vaccines, anti-viral compounds must be relentlessly pursued. In this study, we analyzed the effect of aurintricarboxylic acid (ATA) on SARS-CoV replication in cell culture, and found that ATA could drastically inhibit SARS-CoV replication, with viral production being more than 1000 fold than that in the untreated control. ATA is also shown to be an effective anti-viral for several other viruses, including West Nile Virus and variola virus.
摘要翻译：严重急性呼吸综合征病毒（SARS）是一种冠状病毒，其在2003年煽动了加拿大和几个亚洲国家的区域流行病。新发SARS冠状病毒（SARS-CoV）可以传播给人类，造成严重甚至致命的疾病。由于预防性疫苗开发需要多年才能完成，有些兽医冠状病毒疫苗已经报告出不良反应，因此必须不懈地追求抗病毒化合物。在本研究中，我们分析了神经三羧酸（ATA）对细胞培养中SARS-CoV复制的影响，发现ATA可以显着抑制SARS-CoV复制，其病毒产量比未处理对照高1000倍以上。 ATA还被证明是其他几种病毒的有效抗病毒药物，包括西尼罗河病毒和天花病毒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式